It was reported via a fresenius user facility survey that a peritoneal dialysis (pd) patient experienced peritonitis.In additional follow-up, the patient's pd nurse stated that on (b)(6) 2021, the patient had a pd culture obtained that yielded growth of staphylococcus aureus.It was reported the patient was treated with antibiotic therapy (unknown medication).However, the nurse stated the patient did not recover.Subsequently, on l (b)(6) 2021, the patient had another pd culture obtained which also grew the bacteria staphylococcus aureus.The patient reportedly continued antibiotics and underwent removal of the pd catheter (not a fresenius product).The nurse stated the patient has since been transitioned to hemodialysis and recovered from the peritonitis event.The patient's nurse confirmed the patient did not have any fluid leaks or any issues with a fresenius device or product in relation to the peritonitis event.The nurse attributed the peritonitis to touch contamination during the pd exchange.Moreover, it was indicated the peritonitis persisted due to bacteria in the pd catheter.(b)(4).This report reflects information received by fda in the form of a notification per 803.22 (b)(2).
|